Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.

Danish S, Dogra V, Rauf U, Saghir M, Aslam N

Cureus18 Feb 2025

PMID40125230PMCIDPMC11925721DOI10.7759/cureus.79254PepBankPUB-40125230

Summary

A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide. Starting at 241 lb, she lost 90 lb (over 30% of her body weight) over 65 weeks without side effects. This weight loss exceeded the average reduction reported in previous studies. Additionally, her hypertension resolved, and her glucose levels normalized, illustrating the multifaceted benefits of semaglutide in weight management.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
A 69-year-old woman with morbid obesity lost 90 lb from a starting weight of 241 lb, over 30% of her body weight, over 65 weeks on semaglutide.
In plain wordsOne woman with severe obesity lost over 30% of her body weight over 65 weeks while taking semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight loss
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 65 weeksAs given in this study (human).
Measurements
Starting weight
241 lb
semaglutide
Weight lost
90 lb
semaglutide
Proportion of body weight lost
> 30%
semaglutide
Source sentences
Summary
Starting at 241 lb, she lost 90 lb (over 30% of her body weight) over 65 weeks without side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide.
Show in the study text Report a problemFND-4012523001
02HumanCase report or seriesSafety outcome
A 69-year-old woman lost weight on semaglutide over 65 weeks without side effects.
In plain wordsOne woman lost weight on semaglutide over 65 weeks without side effects.
Peptide
Semaglutide
Outcome
No significant changeSide effects
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 65 weeksAs given in this study (human).
Source sentences
Summary
Starting at 241 lb, she lost 90 lb (over 30% of her body weight) over 65 weeks without side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide.
Show in the study text Report a problemFND-4012523002
03HumanCase report or seriesEfficacy outcome
In a 69-year-old woman treated with semaglutide, hypertension resolved.
In plain wordsIn one woman treated with semaglutide, high blood pressure resolved.
Peptide
Semaglutide
Outcome
DecreaseHypertension resolution
Study
n = 1
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 65 weeksAs given in this study (human).
Source sentences
Summary
her hypertension resolved
1 context sentence(design, population, supporting numbers)
Summary · context
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide.
Show in the study text Report a problemFND-4012523003
04HumanCase report or seriesEfficacy outcome
In a 69-year-old woman treated with semaglutide, glucose levels normalized.
In plain wordsIn one woman treated with semaglutide, glucose levels returned to normal.
Peptide
Semaglutide
Outcome
Not applicableGlucose normalization
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 65 weeksAs given in this study (human).
Source sentences
Summary
her glucose levels normalized
1 context sentence(design, population, supporting numbers)
Summary · context
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide.
Show in the study text Report a problemFND-4012523004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.